23 Jun, 2026 CereVasc, Inc. Completes Enrollment in STRIDE Pivotal Trial of the eShunt® System Carlos Bonilla2026-06-22T20:44:28+00:00June 23rd, 2026| Read More
04 Jun, 2026 CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus Daniel Nunez2026-06-04T09:55:23+00:00June 4th, 2026| Read More
